Could a Once-Daily pill be enough for kidney transplant patients?
NCT ID NCT04773392
First seen Nov 10, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tested whether a once-daily extended-release form of tacrolimus (Envarsus XR) combined with azathioprine works as well as the standard twice-daily tacrolimus with mycophenolate for preventing kidney transplant rejection. The trial planned to enroll 20 kidney transplant recipients but was terminated early. Researchers compared rates of rejection, graft survival, and patient survival between the two groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Southern California
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus (Envarsus XR and immediate-release forms), azathioprine, mycophenolate mofetil/mycophenolic acid, basiliximab, rabbit anti-thymocyte globulin
What this could lead to
If successful, this could show that a simpler once-daily drug regimen is as safe and effective as the standard twice-daily regimen for preventing kidney transplant rejection.
What could go wrong
The trial was terminated early with only 20 participants, so results are limited and may not apply broadly. The study is small and early-phase, so any benefits or risks are uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.